Is Capmatinib effective for systemic bone metastasis from lung cancer?

Capmatinib (Capmatinib) is an oral drug, a tyrosine kinase inhibitor, used to treat ALK rearrangement-positive non-small cell lung cancer. For systemic bone metastasis of lung cancer, capmatinib can play a certain therapeutic role, but its efficacy needs further evaluation. Capmatinib mainly inhibits the growth and spread of tumors by inhibiting tyrosine kinase activity and blocking the proliferation and survival signaling of cancer cells. Clinical study results show that patients taking capmatinib have minimal side effects and are more effective than traditional chemotherapy. Patients with MET exon 14 skipping mutations should be considered for capmatinib therapy. However, the specific effect of efficacy varies depending on individual circumstances, tumor characteristics and other factors.